The Section 8 revocation risk that is quietly sitting in Indian patent portfolios is not a difficult legal problem. It is a docketing problem that becomes a litigation problem, and by the time it surfaces it is usually too late to fix.
The pattern is consistent across the post grant oppositions and Section 64 revocations that practitioners in this space read regularly. The granted Indian patent looks clean on the file wrapper. The Form 3 was filed at the first examination report. The Controller noted satisfaction with the disclosure. The grant issued on schedule. Two years later, sometimes five years later, sometimes at the peak of the product’s commercial life, a well-advised opponent files a post grant opposition or a revocation petition. The ground is not novelty. It is not inventive step. It is Section 8 of the Patents Act, 1970.
What the opponent has done is straightforward. They pulled the patent family on WIPO PatentScope. They searched the USPTO register. They checked the EPO register and CNIPA. All of these are free, publicly indexed, and searchable by patent family. What they found was a US continuation allowed three months after the Indian FER response. A European opposition in which a key claim was amended in the eighteen months before the Indian grant. A CNIPA refusal that was never communicated to the Indian record. None of it on the Indian file wrapper. All of it in the public domain. The petition wrote itself.
What Section 8 Actually Requires
Section 8 of the Patents Act India imposes two distinct obligations that practitioners sometimes conflate and more often under-appreciate in their second dimension.
Section 8(1) requires the applicant to file along with the application, or within six months thereafter, a statement and undertaking regarding foreign applications filed or proposed to be filed in other countries in respect of the same or substantially the same invention. This is the initial disclosure obligation and it is relatively well understood.
Section 8(1)(b) is the obligation that generates the revocations. It requires the applicant to keep the Controller informed, from time to time, of detailed particulars as required of the processing of the application in countries outside India. The phrase from time to time is the operative one. The duty does not terminate at the FER response. It does not terminate when the consolidated Form 3 is filed under the new Rule 12. It runs continuously until the date of grant.
The practical implication is that every event in the foreign patent family that occurs between the FER response and the Indian grant date belongs on the Indian record. A US allowance. A European office action. A claim amendment filed in response to a Japanese examiner. A Chinese refusal. An opposition outcome at the EPO. Each of these is a development in the processing of the application in a country outside India and each falls within the Section 8(1)(b) obligation.
What the Patents Amendment Rules 2024 Changed and What They Did Not
The Patents Amendment Rules, 2024 introduced a genuine procedural simplification that was welcomed by prosecution practitioners. The new Rule 12 permits the applicant to file one consolidated Form 3 within three months of the FER rather than tracking and filing at each individual event in the foreign family. The simplification reduced administrative burden and aligned the filing obligation with the natural rhythm of prosecution.
What the 2024 rules did not change is the statutory obligation under Section 8(1)(b). The Rules govern procedure. The statute governs substance. Rule 12(2) creates a FER-triggered milestone for consolidated filing. It does not shorten the substantive disclosure duty that Section 8(1)(b) imposes. That duty still runs until grant. The consolidated Form 3 filed at the FER captures the state of the foreign family at that moment. It says nothing about what happens in the twelve, eighteen, or twenty-four months between the FER response and the Indian grant.
The complacency that has followed the Rule 12 simplification is the problem the 2024 amendment inadvertently created. Prosecution teams that file the consolidated Form 3 at the FER and consider the Section 8 obligation discharged have closed the door at the FER while leaving the window open until grant. That window is where revocation petitions are built.
The 2024 rules also introduced Rule 12(3), which permits the Controller to use accessible foreign databases to verify information disclosed under Section 8. Some practitioners read this as evidence that the Controller is now taking responsibility for monitoring the foreign family. That reading is incorrect. The Controller’s ability to verify does not extinguish the applicant’s obligation to disclose. The asymmetry between what the Controller happens to check and what the applicant is statutorily required to disclose is precisely the terrain on which Section 64(1)(m) revocations are argued. An opponent does not need the Controller to have found the gap. They need the gap to exist.
The Doctrinal Framework: Chemtura and Sukesh Behl
Two judgments frame the legal exposure and both need to be read together to understand why the doctrinal framework that appears protective is less protective in practice than it looks.
In Chemtura Corporation v. Union of India, 2009 (41) PTC 260 (Del), the Delhi High Court held that disclosure of pending foreign applications under Section 8 is mandatory and that failure attracts revocation under Section 64(1)(m). The interim injunction in that case was vacated on this ground. Chemtura established the baseline: Section 8 failure is a revocation ground and courts will apply it.
The Division Bench in Koninklijke Philips Electronics v. Sukesh Behl, FAO(OS) 16/2014, introduced important qualification. Revocation under Section 64(1)(m) is discretionary, not automatic, and turns on whether the omission was deliberate or a bona fide error. After trial, the Single Judge applied something close to a but-for materiality standard, drawing on the US decision in Therasense v. Becton Dickinson, and refused revocation because the defendants could not prove the omission was deliberate or that the omitted foreign information would have affected the grant decision.
That framework sounds protective. In practice it requires the patentee to argue inadvertence as an affirmative defence, with evidence, before a bench that has already seen the gap on the file wrapper. The well-advised opponent does not gamble on the patentee’s intent. They build the factual record of the gap and let the patentee carry the burden of explaining it. Intent is harder to disprove than disclose.
The Structural Exposure That the Doctrinal Framework Obscures
The reason the Sukesh Behl qualification does not provide the comfort it appears to provide is structural rather than doctrinal.
Section 64(1)(m) carries no limitation period. A post grant opponent proceeding under Section 25(2) has twelve months from the date of grant to file. A revocation petitioner under Section 64 faces no time limit at all. The Section 8 gap that exists on the Indian file wrapper today is available to any opponent or revocation petitioner at any point during the life of the patent. They can bring that fight twenty years into the patent’s life, when the product is at peak revenue, when the manufacturing investment has been fully committed, when the litigation budget to defend the patent is no longer optional.
The Section 8 vulnerability is therefore not a prosecution risk. It is a commercial risk that sits in the patent throughout its life and can be triggered at the moment of maximum inconvenience. The gap that could have been closed with a voluntary Form 3 filing at no cost becomes the ground for a revocation proceeding that will cost multiples of anything the prosecution ever cost to conduct.
The Fix and Why It Is Not Being Applied
The fix for Section 8 exposure is procedurally simple and costs nothing in the direct sense.
File a voluntary Form 3 the moment anything moves in the foreign patent family after the FER response. An allowance in the US. A grant in Europe. An office action in Japan. A refusal in China. An opposition outcome at the EPO. Rule 12(2) creates the FER-triggered consolidated filing milestone. Section 8(1)(b) keeps running after that milestone until the Indian grant. The voluntary Form 3 filed at each subsequent foreign family event closes the gap that a well-advised opponent would otherwise have available to them for the life of the patent.
There is no fee for a voluntary Form 3. There is no prescribed deadline that triggers a late fee. There is no substantive downside to putting information on the Indian record that the applicant is already statutorily required to disclose. It is the single highest-leverage prophylactic act in Indian patent prosecution and most files that come before revocation counsel do not have it.
The reason it is not being applied consistently is a combination of procedural fragmentation and communication breakdown. Foreign associates instructing Indian agents assume the Indian agent is monitoring the foreign family through PAIR or equivalent. Indian agents assume the foreign associate will flag relevant events. Neither assumption is reliable and the statutory duty falls on the applicant, not on either set of counsel.
What Foreign Associates and In-House Teams Need to Do
For foreign associates instructing Indian prosecution counsel, the practice change that Section 8 of the Patents Act India requires is straightforward. Copy India counsel on every foreign family update. Every allowance, every amendment, every grant, every refusal, every opposition development. Do not assume the Indian agent is tracking the PAIR docket. Do not assume the client is monitoring the family across jurisdictions. The duty runs through the client and the client’s counsel, and the voluntary Form 3 that closes the gap needs information that only the foreign associate routinely has in hand.
For in-house teams managing portfolios at scale, the solution is a cross-jurisdiction docketing rule that automatically flags every foreign family event to the India prosecution team for Form 3 assessment. The monthly administrative cost of that rule is rounding error against the litigation cost of a single Section 64(1)(m) revocation at the peak of a product’s commercial life.
For both groups, the disclosure obligation under Section 8 extends beyond bibliographic detail. It covers the prosecution substance of the foreign proceedings. If the US examiner raised a Section 101 objection that materially overlaps with an Indian Section 3(d) issue, that overlap belongs on the Indian record. The opponent’s lawyer will find it on PAIR. The question is whether the patentee put it there first, with an explanation, or whether the opponent finds the gap and writes the explanation themselves in the revocation petition.
